Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
June 22, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the...
Genelux Corporation Announces $18 Million Private Placement
June 12, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares...
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology
May 25, 2023 16:01 ET
|
Genelux Corporation
Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responsesGenerated promising...
Genelux Corporation Announces $33 Million Private Placement
May 15, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares...
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference
April 27, 2023 09:00 ET
|
The Benchmark Company
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- The Benchmark Company is pleased to announce our upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference to be held Tuesday, May 23, 2023....
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
March 23, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a...
Global Oncolytic Virus Therapy Clinical Pipeline Insight 2028
March 20, 2023 03:21 ET
|
KuicK Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview: Global Oncolytic Virus Immunotherapy Therapy Market...
At 9.6% CAGR, Global Cancer Gene Therapy Market Size Estimated to Cross USD 3.99 Billion Value By 2030: Polaris Market Research
February 24, 2023 07:54 ET
|
Polaris Market Research & Consulting LLP
New York, NY, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Polaris Market Research has published a new research report titled “Cancer Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By...
Global Cancer Gene Therapy Market to Reach $7.8 Billion by 2030
February 02, 2023 14:16 ET
|
ReportLinker
New York, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Gene Therapy Industry" - https://www.reportlinker.com/p05956210/?utm_source=GNW Food...
Genelux Corporation Announces Pricing of Initial Public Offering
January 25, 2023 21:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of...